Cipla Ltd.

92 articles about Cipla Ltd.

• Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

  1/8/2024

  Pulmatrix today announced that it has entered into a further amendment to its agreement with Cipla for the development of PUR1900 in the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA). 

• InvaGen Pharmaceuticals Issues Voluntary Nationwide Recall of Vigabatrin for Oral Solution, USP 500mg due to Leaking Sachets

  12/9/2023

  Cipla Limited announced that its wholly-owned subsidiary, InvaGen Pharmaceuticals Inc. is voluntarily recalling one lot of Vigabatrin for Oral Solution, USP 500mg, to the consumer level.

• Cipla Issues Voluntary Nationwide Recall of Six batches of Albuterol Sulfate Inhalation Aerosol, 90 mcg (200 Metered Inhalation) due to Container Defect

  7/7/2023

  Cipla Limited, announced that its wholly-owned subsidiary Cipla US is voluntarily recalling six batches of Albuterol Sulfate Inhalation Aerosol, 90 mcg manufactured in November 2021 to the consumer level.

• Cipla Announces Launch of Leuprolide Acetate Injection Depot (22.5mg)

  11/30/2022

  Cipla Limited and its wholly owned subsidiary Cipla USA Inc., announced the launch of Leuprolide Acetate Injection Depot 22.5mg.

• Cipla and DNDi launch child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa

  6/14/2022

  The South African Health Products Regulatory Authority has approved a sweet-tasting, heat-stable, '4-in-1' fixed-dose combination of four antiretroviral treatments composed of abacavir, lamivudine, lopinavir, and ritonavir that is specifically designed for infants and young children with HIV.

• Cipla to Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/12/2022

  Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as "Cipla" today announced that it will participate at the 40th Annual J.P. Morgan Healthcare Conference,

• Cipla receives final approval for generic version of Novartis Pharmaceuticals Corporation Durezol® (Difluprednate Ophthalmic Emulsion 0.05%)

  8/12/2021

  Cipla Limited today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05% from the United States Food and Drug Administration (US FDA).

• Cipla receives final approval for generic version of Sunovion Pharmaceuticals, Inc.'s Brovana® (Arformoterol Tartrate Inhalation Solution 15 mcg/ 2mL)

  6/23/2021

  Cipla Limited announced that it has received final approval for its Abbreviated New Drug Application for Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL from the United States Food and Drug Administration.

• Cipla Gulf and Alvotech Expand Partnership for Commercialization of Biosimilars in Australia and New Zealand

  3/2/2021

  Gulf FZ LCC, subsidiary of Cipla Limited referred to as “Cipla” and biopharmaceutical company Alvotech announced that they are expanding their partnership for the marketing and distribution of four biosimilar medicines in Australia and New Zealand.

• Cipla and Stempeutics collaborate for launch of Stempeucel®, first 'Made in India' Cell Therapy to treat Critical Limb Ischemia (CLI)

  8/21/2020

  Developed by Stempeutics over a period of twelve years, breakthrough treatment designed to address root cause of the disease at an affordable cost

• Cipla Receives Final Approval for Generic Version of Shire's Firazyr® (Icatibant Injectable Pre-Filled Syringe 30mg/3mL)

  7/14/2020

  Cipla Limited and hereafter referred to as announced that it has received final approval for its Abbreviated New Drug Application for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration.

• Cipla Launches CIPREMI (remdesivir Lyophilised Powder for Injection 100 mg), the Only U.S. FDA Approved Emergency Use Authorisation (EUA) Treatment for Patients With Severe COVID-19 Disease

  6/22/2020

  Cipla Limited announced the launch of remdesivir under its brand name CIPREMI.

• Cipla Receives Final Approval for Generic Version of Migranal® (Dihydroergotamine Mesylate Nasal Spray 4mg/mL) With a Competitive Generic Therapy Designation

  5/21/2020

  Cipla Limited announced that it has received final approval for its Abbreviated New Drug Application for Dihydroergotamine Mesylate Nasal Spray 4mg/mL from the United States Food and Drug Administration with a Competitive Generic Therapy designation.

• Cipla Files ANDA for Generic Version of GSK's Advair Diskus®

  5/19/2020

  Cipla Limited announced its submission of an Abbreviated New Drug Application for Fluticasone propionate and Salmeterol inhalation powder to the United States Food and Drug Administration.

• KYPROLIS® (carfilzomib) Patents Upheld Against Generic Manufacturer

  5/5/2020

  Amgen today announced that the U.S. District Court in Delaware issued a decision upholding the validity of patent claims from three patents that protect Amgen's multiple myeloma therapy KYPROLIS®.

• Cipla Receives Final Approval for Generic Version of Proventil® HFA Inhalation Aerosol (Albuterol Sulfate Inhalation Aerosol 90mcg (Base)/Actuation)

  4/9/2020

  Cipla Limited (BSE: 500087) (NSE: CIPLA EQ); (and hereafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol 90mcg (base)/actuation, from the United States Food and Drug Administration (US FDA). Cipla's Albuterol S

• Cipla Receives Final Approval for Generic Version of AstraZeneca Pharmaceutical's Nexium® (Esomeprazole for Oral Suspension 10mg, 20mg and 40mg)

  3/27/2020

   Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and hereafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Esomeprazole for Oral Suspension 10mg, 20mg and 40mg from the

• Cipla Announces the Launch of Daptomycin for Injection, 500 mg/vial, Single-dose Vials (for Intravenous use only)

  9/26/2019

  Cipla Limited and its subsidiary Cipla USA, Inc., announce the launch of Daptomycin for Injection, 500mg/vial, single-dose vial, AP-rated generic equivalent of Cubicin® for Injection in the United States.

• Pulmatrix and Cipla Announce First Patient Dosed in Phase 2 Trial Evaluating Pulmazole for Treatment of Allergic Bronchopulmonary Aspergillosis in Patients with Asthma

  9/18/2019

  Phase 2 clinical trial initiated and enrollment progressing across 24 sites

• InvaGen (a Cipla Subsidiary) Receives Final Approval for Generic Version of Pfizer's Lyrica® (Pregabalin Capsules, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg)

  7/22/2019

  InvaGen Pharmaceuticals, Inc., a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited announced the receipt of final approval for its Abbreviated New Drug Application for Pregabalin Capsules, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg from the United States Food and Drug Administration.